8-K: Upexi Raises $7.4M in Direct Offering, Amends Warrants

Upexi, Inc. secured $7.4 million in a registered direct offering with a single institutional investor, issuing common stock and new warrants, while also amending existing warrants to reduce exercise and redemption prices.

Summary

• Upexi, Inc. completed a registered direct offering, raising approximately $7.4 million in gross proceeds.
• The offering involved the sale of 6,337,000 shares of common stock and accompanying warrants to purchase an equal number of shares to a single institutional investor.
• The combined offering price was $1.17 per share of common stock and accompanying warrant.
• The new warrants have an exercise price of $1.50 per share, are immediately exercisable, and expire in five years (February [*], 2031).
• The Company may receive up to an additional $9.5 million if the new warrants are exercised for cash.
• Existing warrants issued on December 1, 2025, to the same purchaser, for 3,289,474 shares, were amended.
• The exercise price of these amended warrants was reduced from $4.00 to $2.83 per share.
• The redemption price trigger for the amended warrants was reduced from $8.50 to $7.00 per share.
• The amendment to the existing warrants requires stockholder approval, to be sought at a special meeting within 45 days of February 5, 2026, or by June 2, 2026, if earlier.
• A.G.P./Alliance Global Partners acted as the exclusive placement agent, receiving a 5.0% cash fee on gross proceeds and a 5.0% fee on warrant exercise proceeds, plus expense reimbursements up to $100,000.
• Company directors and executive officers entered into 15-day lock-up agreements.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative development for existing shareholders due to the substantial dilution from the new offering and, more critically, the highly unfavorable amendment to existing warrants, which drastically reduces their exercise price and redemption trigger for a single institutional investor. While capital was raised, the terms appear to heavily favor the investor at the expense of current equity holders.

Positives

• Successfully raised $7.4 million in gross proceeds, enhancing liquidity.
• Potential for an additional $9.5 million upon cash exercise of the new warrants.
• Strengthens the company's balance sheet for general corporate purposes and its Solana (SOL) maximum return strategy.

Negatives

• Issuance of 6,337,000 new shares and warrants will result in significant dilution for existing shareholders.
• The exercise price of the new warrants ($1.50) is relatively low compared to the previous warrant exercise price.
• Amendment of previously issued warrants to reduce their exercise price from $4.00 to $2.83 and redemption trigger from $8.50 to $7.00 is unfavorable for existing shareholders as it makes it easier for the holder to profit and potentially increases future dilution at a lower price.
• The need for stockholder approval for the warrant amendment introduces uncertainty and potential delays.
• Placement agent fees and expenses will reduce the net proceeds received by the company.

Risks

• Dilution of outstanding shares of Common Stock due to the issuance of new shares and potential exercise of warrants.
• Market price volatility of the Common Stock could be negatively impacted by purchasers' trading activities, including short sales or derivative transactions.
• Hedging activities by purchasers could reduce the value of existing stockholders' equity interests.
• Failure to timely deliver Warrant Shares upon exercise could result in liquidated damages and buy-in compensation for the Company.
• The Company's ability to maintain its listing or quotation on its Trading Market.
• The Company's ability to renew existing insurance coverage or obtain similar coverage without a significant increase in cost.
• Potential for litigation or regulatory actions, including claims of violation of federal or state securities laws or breach of fiduciary duty.
• Failure to obtain stockholder approval for the amendment to the previously issued warrants could impact the terms of those securities.

Future Outlook

The Company expects to use the net proceeds from the offering for working capital, general corporate purposes, and its internally managed, SOL maximum return strategy. It aims to acquire and hold as much Solana (SOL) as possible, benefiting from potential price appreciation, and utilizing intelligent capital issuance, staking, and discounted locked token purchases.

Management Comments

• Upexi, Inc. (NASDAQ: UPXI) (the Company or Upexi), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it has entered into a definitive agreement with a single institutional investor for the sale and issuance of 6,337,000 shares of common stock of the Company and warrants to purchase up to 6,337,000 shares of common stock at a combined offering price of $1.17 per share of common stock and accompanying warrant, in a registered direct offering.
• The Company expects to use the net proceeds from the Offering for working capital, general corporate purposes and its internally managed, SOL maximum return strategy.
• Upexi, Inc. (Nasdaq: UPXI) is a leading digital asset treasury company, where it aims to acquire and hold as much Solana (SOL) as possible in a disciplined and accretive fashion.
• Upexi utilizes three key value accrual mechanisms in intelligent capital issuance, staking, and discounted locked token purchases.
• The Company operates in a risk-prudent fashion to position itself for any market environment and to appeal to investors of all kinds, and it currently holds over two million SOL.

Industry Context

StockSavvy.ai notes that Upexi's strategy to focus on Solana (SOL) as a digital asset treasury company positions it within the rapidly evolving cryptocurrency and blockchain sector. This capital raise could enable Upexi to further execute its 'SOL maximum return strategy,' potentially increasing its holdings of Solana, which is a key competitor to Ethereum in the smart contract platform space. The company's dual identity as a consumer brands owner alongside its digital asset strategy presents a unique, albeit potentially complex, business model in the market.

Comparison to Industry Standards

• The offering price of $1.17 per share and the new warrant exercise price of $1.50 are relatively low compared to the amended warrant's new exercise price of $2.83, suggesting a potentially aggressive pricing strategy to attract capital or reflect current market conditions for UPXI.
• The reduction in exercise price for existing warrants from $4.00 to $2.83 and the redemption trigger from $8.50 to $7.00 for a single institutional investor is a significant concession, which could be viewed negatively when compared to standard equity financing terms that typically aim to protect existing shareholder value.
• The 5.0% placement agent fee is within the typical range for registered direct offerings, which can vary based on deal size and market conditions.
• Upexi's strategy of holding over two million SOL positions it as a significant player in the Solana ecosystem, comparable to other large holders or investment funds focused on specific cryptocurrencies, though its dual business model is less common.

Corporate Governance

Stakeholder Impact

• Shareholders: Significant dilution from the new share issuance and the unfavorable amendment of existing warrants, which reduces the exercise price and redemption trigger, making it easier for the institutional investor to profit at a lower stock price.
• Institutional Investor (Purchaser): Benefits from acquiring new shares and warrants at a low combined price, and from the significantly improved terms of their previously held warrants.
• Company: Gains $7.4 million in gross proceeds and potential additional $9.5 million, improving liquidity and funding its SOL strategy, but at a high cost of dilution and favorable terms for the investor.
• Placement Agent (A.G.P./Alliance Global Partners): Earns substantial fees (5.0% of gross proceeds and 5.0% of warrant exercise proceeds) and expense reimbursements.

Next Steps

• Closing of the offering, expected on or about February 9, 2026.
• Filing of a prospectus supplement with the SEC on February 9, 2026.
• Company to hold a special meeting of stockholders at the earliest practicable date, but no later than 45 days after February 5, 2026, to obtain approval for the amendment to the original warrants.
• If stockholder approval is not obtained at the first meeting, the Company will call a meeting every two months thereafter to seek approval until the earlier of approval or June 2, 2026.
• The Company will use net proceeds for working capital, general corporate purposes, and its internally managed SOL maximum return strategy.

Key Dates

Recommendation

The terms of this offering and the amendment to existing warrants are highly detrimental to current shareholders. The significant dilution from the new shares and the drastic reduction in the exercise price and redemption trigger for previously issued warrants to a single institutional investor suggest a substantial transfer of value from existing equity holders to the new investor. This indicates a weak negotiating position for the company or a desperate need for capital, making the stock a strong sell for existing investors given the unfavorable terms.

Keywords

Upexi Inc., UPXI, Registered Direct Offering, Common Stock, Warrants, Solana, Digital Asset Treasury, Capital Raise, Dilution, SEC Filing, Form 8-K, Equity Financing, Institutional Investor, Stock Warrants, Corporate Finance